

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MADISON *et al.*
Serial No.: 09/776,191
Filed: February 2, 2001
Conf. No.: 3237
For: *NUCLEIC ACID
MOLECULES ENCODING
TRANSMEMBRANE
SERINE PROTEASES, THE
ENCODED PROTEINS AND
METHODS BASED
THEREON*
Art Unit: 1646
Examiner: Unassigned

RECEIVED

APR 28 2003

TECH CENTER 1600/2900

RECEIVED
TECH CENTER 1600/2900
03 APR 24 PM 12:50

TRANSMITTAL LETTER

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:

Transmitted herewith via hand delivery are a Supplemental Information Disclosure Statement, Form PTO-1449 (3 pages) and cited references for filing in connection with the above-identified application.

- [X] The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman
Registration No. 33,779

Dated: April 23, 2003
Attorney Docket No. 24745-1607
Address all correspondence to:
Stephanie L. Seidman
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com

RECEIVED

APR 28 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Madison *et al.*
Serial No.: 09/776,191
Filed: February 2, 2001
Conf. No.: 3237
For: *NUCLEIC ACID
MOLECULES ENCODING
TRANSMEMBRANE
SERINE PROTEASES, THE
ENCODED PROTEINS AND
METHODS BASED
THEREON*
Art Unit: 1646
Examiner: Unassigned

#14
D.90
4/29/03
RECEIVED
TECH CENTER 1600/2900
03 APR 24 PM 12:50

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE
WITH 37 C.F.R. §§ 1.97-1.98**

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Since this Supplemental Information Disclosure Statement is filed before the receipt of a first Office Action on the merits for the above-captioned application, no filing fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98.

U.S.S.N. 09/776,191
MADISON, *et al.*
INFORMATION DISCLOSURE STATEMENT

Form PTO-1449 (3 pages) and copies of the cited documents are provided herewith.

The cited documents, listed on Forms PTO-1449 and supplied herewith, are in the English language, with the exception of item V. This item, which is in the German language, is provided with English language abstract (item AB). Hence, in accordance with the requirements of 37 C.F.R. § 1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following U.S. and International applications, which are commonly owned and/or have one or more inventors in common:

U.S.S.N.
60/394,347

Filing Date
07/02/02

Docket No.
24745-P1625

Additionally, documents A, C, D, H, M, O-U and W listed on the Form PTO-1449 and supplied herewith are the publications of U.S. and International applications which are commonly owned and/or have one or more inventors in common.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.


U.S.S.N. 09/776,191
MADISON, *et al.*
INFORMATION DISCLOSURE STATEMENT

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

* * *

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:


Stephanie L. Seidman
Registration No. 33,779

Date: April 23, 2003
Attorney Docket No. 24745-1607
Address all correspondence to:
Stephanie L. Seidman
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24745-1607	SERIAL NO. 09/776,191
	APPLICANT Madison <i>et al.</i> ,	
	FILING DATE February 2, 2001	GROUP 1646

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

RECEIVED
APR 25 2003
TECH CENTER 1800/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	0	0	0	8	3	7	2	01/09/03	Madison <i>et al.</i>	435	226	03/13/02
	B	0	0	3	7	8	5	7	03/28/02	Semple <i>et al.</i>	514	19	12/07/00
	C	0	1	0	7	2	6	6	08/08/02	Lim-Wilby <i>et al.</i>	514	339	12/11/01
	D	0	1	6	0	9	6	2	10/31/02	Saksena <i>et al.</i>	514	19	07/19/01
	E	5	5	8	9	1	5	4	12/31/96	Anderson	424	1.41	11/22/94
	F	5	8	0	4	4	1	0	09/03/98	Yamaoka <i>et al.</i>	435	69.1	07/28/95

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	G	0	0	5	5	1	2	4	09/21/00	PCT				
	H	0	1	3	6	3	5	1	05/25/01	PCT				
	I	0	1	3	6	6	4	5	05/25/01	PCT				
	J	0	1	4	6	4	0	7	06/28/01	PCT				
	K	0	1	4	9	8	6	4	07/12/01	PCT				
	L	0	1	5	4	4	7	7	08/02/01	PCT				
	M	0	2	0	0	8	1	87	01/31/02	PCT				
	N	0	2	0	0	8	6	0	01/03/02	PCT				
	O	0	2	0	4	8	0	97	06/20/02	PCT				
	P	0	2	0	7	2	7	86	09/19/02	PCT				
	Q	0	2	0	7	7	2	63	10/03/02	PCT				
	R	0	2	0	7	7	2	67	10/03/02	PCT				
	S	0	2	0	8	2	5	1	01/31/02	PCT				
	T	0	2	0	9	2	8	41	11/21/02	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24745-1607	SERIAL NO. 09/776,191
	APPLICANT Madison <i>et al.</i> ,	
	FILING DATE February 2, 2001	GROUP 1646

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
	U	0	2	0	9	5	0	07	02/07/02	PCT				
	V	0	2	5	7	3	5	2	03/02/88	EP				X*
	W	0	3	0	0	4	6	81	01/16/03	PCT				
	X	9	5	2	3	2	2	2	08/31/95	PCT A				
	Y	9	6	3	0	3	5	3	10/03/96	PCT A				
	Z	9	7	2	1	6	9	0	06/19/97	PCT A				
	AA	9	9	1	7	7	9	0	04/15/99	PCT A				

X* = An English Language Derwent is provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AB	Derwent#007409639, WPI Acc. No. 1988-043574/198807, for European Patent Application, EP 257352, "Determining free portion of e.g. thyroxine in presence of binder - by reaction with antibody which does not effect bound-unbound equilibrium, then reacting cross reactive tracer with antibody".
AC	Fernandez <i>et al.</i> , "N-Succinyl-(β -alanyl-L-alanyl-L-leucyl)doxorubicin: An Extracellularly Tumor-Activated Prodrug Devoid of Intravenous Acute Toxicity", <i>J Med Chem</i> , 2 pages, (2001)
AD	Harris <i>et al.</i> , "Rapid and general profiling of protease specificity by using combinatorial fluorigenic substrate libraries," <i>PNAS</i> <u>97</u> : 7754-7759 (2000)
AE	Liu <i>et al.</i> , "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids", <i>Proc Natl Acad Sci USA</i> , <u>93</u> :8618-8623 (1996)
AF	Pastan <i>et al.</i> , "Recombinant Toxins for Cancer Treatment", <i>Science</i> , <u>254</u> :1173-1177; (1991)
AG	Schmidt, M. and W. Wels, "Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF α ", <i>British Journal of Cancer</i> , <u>74</u> :853-862 (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24745-1607	SERIAL NO. 09/776,191
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Madison <i>et al.</i> ,	
	FILING DATE February 2, 2001	GROUP 1646

	AH	Trouet <i>et al.</i> , "Extracellularly Tumor-activated Prodrugs for the Selective Chemotherapy of Cancer: Application to Doxorubicin and Preliminary <i>in Vitro</i> and <i>in Vivo</i> Studies", <i>Cancer Research</i> , <u>61</u> :2843-2846 (2001)
--	----	---

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.